Immunogen reports a net loss of $12.1 million in third quarter 2010

[News]

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended March 31, 2010 - the third quarter of the Company's 2010 fiscal year (3QFY10).

More... (http://www.news-medical.net/news/20100430/Immunogen-reports-a-net-loss-of-24121-million-in-third-quarter-2010.aspx)